Cerebrospinal Fluid (CSF) Raltegravir Substudy
|ClinicalTrials.gov Identifier: NCT00718029|
Recruitment Status : Unknown
Verified July 2008 by University of California, San Diego.
Recruitment status was: Enrolling by invitation
First Posted : July 18, 2008
Last Update Posted : July 24, 2008
The purpose of this study is to measure concentrations of Raltegravir in cerebrospinal fluid.
The hypotheses are:
- Raltegravir concentrations in CSF will be measurable
- Raltegravir concentrations in CSF will remain constant, while plasma concentrations vary widely leading to highly variable CSF-to-plasma ratios.
- Following at least 4 weeks of Raltegravir-containing combination therapy, HIV RNA levels in CSF will be below 50 copies/mL in all subjects.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||15 participants|
|Official Title:||MK: Raltegravir Concentrations in Cerebrospinal Fluid|
|Study Start Date :||July 2008|
|Estimated Primary Completion Date :||July 2009|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00718029
|Principal Investigator:||Scott L Letendre, MD||University of California, San Diego AntiViral Research Center|